Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Disease/ Diagnostics

show results
Refine your search

Search term:

Results 1 - 10 of 26 > >>
EC Number Disease PubMed ID Title of Publication Category Confidence Level
Show all pathways known for 6.3.4.21Display the word mapDisplay the reaction diagram Show all sequences 6.3.4.21Bone Marrow Failure Disorders 32098966 The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. unassigned 0
Show all pathways known for 6.3.4.21Display the word mapDisplay the reaction diagram Show all sequences 6.3.4.21Carcinoma 24204194 Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618. diagnostic usage
ongoing research
therapeutic application
unassigned
3
2
3
0
Show all pathways known for 6.3.4.21Display the word mapDisplay the reaction diagram Show all sequences 6.3.4.21Carcinoma, Non-Small-Cell Lung 24204194 Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618. diagnostic usage
ongoing research
therapeutic application
unassigned
3
2
3
0
Show all pathways known for 6.3.4.21Display the word mapDisplay the reaction diagram Show all sequences 6.3.4.21Glioblastoma 19703994 The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. causal interaction
diagnostic usage
ongoing research
therapeutic application
4
1
1
4
Show all pathways known for 6.3.4.21Display the word mapDisplay the reaction diagram Show all sequences 6.3.4.21Glioblastoma 22570471 Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner. causal interaction
therapeutic application
unassigned
3
1
0
Show all pathways known for 6.3.4.21Display the word mapDisplay the reaction diagram Show all sequences 6.3.4.21Glioma 33197538 NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation. causal interaction
therapeutic application
unassigned
2
1
0
Show all pathways known for 6.3.4.21Display the word mapDisplay the reaction diagram Show all sequences 6.3.4.21Glucose Intolerance 27592202 Tissue-specific regulation of sirtuin and nicotinamide adenine dinucleotide biosynthetic pathways identified in C57Bl/6 mice in response to high-fat feeding. causal interaction
unassigned
3
0
Show all pathways known for 6.3.4.21Display the word mapDisplay the reaction diagram Show all sequences 6.3.4.21Lymphoma 21492230 Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas. causal interaction
diagnostic usage
ongoing research
therapeutic application
4
3
4
4
Show all pathways known for 6.3.4.21Display the word mapDisplay the reaction diagram Show all sequences 6.3.4.21Neoplasms 19703994 The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. causal interaction
diagnostic usage
ongoing research
therapeutic application
4
1
1
4
Show all pathways known for 6.3.4.21Display the word mapDisplay the reaction diagram Show all sequences 6.3.4.21Neoplasms 20515945 A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. causal interaction
therapeutic application
unassigned
4
4
0
Results 1 - 10 of 26 > >>